Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION.
Jan KlokaBenjamin FriedrichsonStephanie DauthAnn Christina FoldenauerAnita Bulczak-SchadendorfMaria J G T VehreschildFrancisco Maio MatosAntoni Riera-MestreAntoinette D I van AsseltEdoardo De RobertisVilma Traskaite JuskevicienePatrick MeybohmDana TomescuKarine LacombeCoen D A StehouwerKai Zacharowskinull nullPublished in: Trials (2022)
EudraCT 2021-005059-35 . Registered on 12 December 2021. Study Code TMP-2204-2021-47.